Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11009926 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL9147219 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL14862830 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL10719856 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL5228161 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL18800105 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL16160401 | 0.98 | CYP1A2 (0.54) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL5878611 | 0.98 | CYP1A2 (0.54) | CYP1A2ALDH1A1L3MBTL1PPARGNOS1 | |
| SCHEMBL7804803 | 0.93 | CYP1A2 (0.50) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 | |
| SCHEMBL7741474 | 0.93 | CYP1A2 (0.53) | CYP1A2ALDH1A1L3MBTL1NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492574-B2 | Methods for preparing dioranozinc compounds | CHARETTE ANDRE (CA) | 2013-07-23 | — | — | US | disclosed |
| US-8492574-B2 | Methods for preparing dioranozinc compounds | CHARETTE ANDRE (CA) | 2013-07-23 | — | — | US | disclosed |
| US-8492574-B2 | Methods for preparing dioranozinc compounds | CHARETTE ANDRE (CA) | 2013-07-23 | — | — | US | disclosed |
| US-20100121089-A1 | Methods for preparing dioranozinc compounds | CHARETTE ANDRE | 2010-05-13 | — | — | US | disclosed |
| US-20100121089-A1 | Methods for preparing dioranozinc compounds | CHARETTE ANDRE | 2010-05-13 | — | — | US | disclosed |
| US-20100121089-A1 | Methods for preparing dioranozinc compounds | CHARETTE ANDRE | 2010-05-13 | — | — | US | disclosed |
| WO-2008134890-A1 | METHODS FOR PREPARING DIORGANOZINC COMPOUNDS | VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121089-A1 | Methods for preparing dioranozinc compounds | ZRANB2, PRMT1, RDX | CYP1A2 26/4885ALDH1A1 2252/4885L3MBTL1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.